SINOVAC-BIOTECH
6.9.2022 12:01:43 CEST | Business Wire | Press release
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac®, mRNA, or adenovirus vector COVID-19 vaccine. This study is the world's first study researching multivalent inactivated COVID-19 vaccine.
In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited. Participants belonging to the heterologous scheme are individuals who had received two CoronaVac® doses, and two boosters of mRNA-based or viral vector-based vaccines, while participants of the homologous scheme had received four doses of CoronaVac®. Individuals from the heterologous scheme will randomly receive a booster dose with the Omicron, Trivalent, or CoronaVac® vaccines, while individuals from the homogeneous group will randomly receive a booster dose of the Omicron or the trivalent vaccines.
Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, “SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine. We are proud of the fact that CoronaVac® can protect individuals as young as 6 months of age and this clinical approval will allow even better vaccine protection.”
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis. Its COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. Its Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. Its EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Industry-Leading FPGA Innovations at FPGA Conference Europe 202616.6.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA Conference Europe. Lattice will participate in various speaker sessions to showcase how low power FPGAs are driving innovation across multiple sectors. The company will also demonstrate its latest FPGA technology advancements in physical AI, advanced connectivity, security, and more. Who: Lattice Semiconductor What / When (GMT+2): June 30 – July 2: Lattice Presentations & Demo Showcase Speaker sessions: Day 1 – 3 Speaker Sessions: Lattice FPGA deep dive sessions spanning physical AI, advanced connectivity, security, and design tools Date Time Session June 30 9:45 a.m. FPGA Verification and Testing by Arrow 11:15 a.m. Trusted Resilience Edge: Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act 12 p.m. SIPHashIP for Embedded Security: Enabling RED Compliance and CRA Readiness in Smart AR/VR Systems 2:15 p.m. Foundations of FPGA Security
IQM Deploys Its First U.S. Quantum Computer at Oak Ridge National Laboratory16.6.2026 20:53:00 CEST | Press release
Pathfinder, a 20-qubit IQM Radiance system, is now operational at the home of Frontier, the world's most powerful supercomputer for open science. It’s ORNL's first commercially procured quantum computer and IQM's first system on U.S. soil. It will be connected to high-performance computing systems in the National Center for Computational Sciences Technology Integration Group's test bed. ORNL owns and operates the system on its own campus. IQM's deployment model gives customers direct ownership and control of their quantum infrastructure, including the IP. IQM has sold 23 full-stack quantum systems worldwide, more on-premises systems than any other manufacturer. The deployment expands IQM's commercial presence in the United States ahead of its planned Nasdaq listing through its merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). The Department of Energy's Oak Ridge National Laboratory (ORNL) today launched Pathfinder, the first commercially procured quantum computer at ORNL, built
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 19:00:00 CEST | Press release
Court orders Siemens to halt production and recall and destroy products across Germany, France and the Netherlands Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1
RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 18:30:00 CEST | Press release
Wavecrest Growth Partners invests to enable combination and support growth of the combined company RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, d
Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 17:42:00 CEST | Press release
Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom